Integrative Research Laboratories Sweden: € 50k

IRLAB aims to address the challenge in Parkinson’s Disease treatment by clinically validating its novel compound, IRL790, aimed at reducing symptoms of PD-LIDs and Parkinson’s disease psychosis. IRL Sweden was granted € 50k from the SME Instrument HORIZON 2020, phase 1. GAEU’s team at Horizon 2020 Centre of Excellence wrote the proposal.

MORE REFERENCES

FOLLOW US